[{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"WestPark Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Public Offering","leadProduct":"TTX-MC138","moa":"microRNA-10b","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"injection","sponsorNew":"TransCode Therapeutics \/ WestPark Capital","highestDevelopmentStatusID":"6","companyTruncated":"TransCode Therapeutics \/ WestPark Capital"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Funding","leadProduct":"TTX-MC138","moa":"microRNA-10b","graph1":"Oncology","graph2":"Preclinical","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"TransCode Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Funding","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Preclinical","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TransCode Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"TransCode Therapeutics \/ National Cancer Institute"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Preclinical","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"TransCode Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"PD-1\/PD-L1","graph1":"Oncology","graph2":"Preclinical","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"TransCode Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"TTX-MC138","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TransCode Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"TTX-MC138","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TransCode Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"TTX-RIGA","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"TransCode Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"TTX-MC138","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"5","companyTruncated":"TransCode Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"BRAIN Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ BRAIN Biotech","highestDevelopmentStatusID":"2","companyTruncated":"TransCode Therapeutics \/ BRAIN Biotech"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"TTX-MC138","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"TransCode Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Funding","leadProduct":"TTX-MC138","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"TransCode Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"White Lion Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Financing","leadProduct":"TTX-MC138","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ White Lion Capital","highestDevelopmentStatusID":"6","companyTruncated":"TransCode Therapeutics \/ White Lion Capital"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"TTX-MC138","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TransCode Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"TTX-MC138","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"6","companyTruncated":"TransCode Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"TTX-MC138-NODAGA-Cu64","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TransCode Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"TTX-MC138-NODAGA-Cu64","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TransCode Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"TTX-MC138","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TransCode Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"TTX-MC138","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"TransCode Therapeutics \/ ThinkEquity","highestDevelopmentStatusID":"6","companyTruncated":"TransCode Therapeutics \/ ThinkEquity"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"TTX-MC138-NODAGA-Cu64","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"TransCode Therapeutics \/ ThinkEquity","highestDevelopmentStatusID":"6","companyTruncated":"TransCode Therapeutics \/ ThinkEquity"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"TTX-RIGA","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"TransCode Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"TTX-MC138","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ ThinkEquity","highestDevelopmentStatusID":"4","companyTruncated":"TransCode Therapeutics \/ ThinkEquity"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"TTX-MC138-NODAGA-Cu64","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TransCode Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"TTX-MC138","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TransCode Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"TTX-MC138","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"5","companyTruncated":"TransCode Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"TTX-MC138","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"TransCode Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"6","companyTruncated":"TransCode Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"TTX-MC138","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TransCode Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"TransCode Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"7","companyTruncated":"TransCode Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"TTX-MC138","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TransCode Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"TransCode Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"7","companyTruncated":"TransCode Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"TTX-MC138","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"TransCode Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Debiopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"TTX-MC138","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TransCode Therapeutics \/ Debiopharm","highestDevelopmentStatusID":"6","companyTruncated":"TransCode Therapeutics \/ Debiopharm"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"TTX-MC138","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TransCode Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"TTX-MC138","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ ThinkEquity","highestDevelopmentStatusID":"14","companyTruncated":"TransCode Therapeutics \/ ThinkEquity"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"TTX-MC138","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ ThinkEquity","highestDevelopmentStatusID":"14","companyTruncated":"TransCode Therapeutics \/ ThinkEquity"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"TTX-MC138","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"TransCode Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"TTX-MC138","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"TransCode Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Funding","leadProduct":"TTX-MC138","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"14","companyTruncated":"TransCode Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"TTX-MC138","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"TransCode Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"TTX-MC138","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"TransCode Therapeutics \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by TransCode Therapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
